Inhibition of heat-shock protein 90 reduces Ebola virus replication

Darci R. Smith, Sarah McCarthy, Andrew Chrovian, Gene Olinger, Andrea Stossel, Thomas Geisbert, Lisa E. Hensley, John H. Connor

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Ebola virus (EBOV), a negative-sense RNA virus in the family Filoviridae, is known to cause severe hemorrhagic fever in humans and other primates. Infection with EBOV causes a high mortality rate and currently there is no FDA-licensed vaccine or therapeutic treatment available. Recently, heat-shock protein 90 (Hsp90), a molecular chaperone, was shown to be an important host factor for the replication of several negative-strand viruses. We tested the effect of several different Hsp90 inhibitors including geldanamycin, radicicol, and 17-allylamino-17-demethoxygeldanamycin (17-AAG; a geldanamycin analog) on the replication of Zaire EBOV. Our results showed that inhibition of Hsp90 significantly reduced the replication of EBOV. Classic Hsp90 inhibitors reduced viral replication with an effective concentration at 50% (EC50) in the high nanomolar to low micromolar range, while drugs from a new class of Hsp90 inhibitors showed markedly more potent inhibition. These compounds blocked EBOV replication with an EC50 in the low nanomolar range and showed significant potency in blocking replication in primary human monocytes. These results validated that Hsp90 is an important host factor for the replication of filoviruses and suggest that Hsp90 inhibitors may be therapeutically effective in treating EBOV infection.

Original languageEnglish (US)
Pages (from-to)187-194
Number of pages8
JournalAntiviral Research
Volume87
Issue number2
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Ebolavirus
HSP90 Heat-Shock Proteins
Virus Replication
tanespimycin
Ebola Hemorrhagic Fever
Filoviridae
Molecular Chaperones
RNA Viruses
Primates
Monocytes
Fever
Vaccines
Viruses
Mortality

Keywords

  • Ebola virus
  • Hsp90
  • Therapeutic

ASJC Scopus subject areas

  • Virology
  • Pharmacology
  • Medicine(all)

Cite this

Smith, D. R., McCarthy, S., Chrovian, A., Olinger, G., Stossel, A., Geisbert, T., ... Connor, J. H. (2010). Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antiviral Research, 87(2), 187-194. https://doi.org/10.1016/j.antiviral.2010.04.015

Inhibition of heat-shock protein 90 reduces Ebola virus replication. / Smith, Darci R.; McCarthy, Sarah; Chrovian, Andrew; Olinger, Gene; Stossel, Andrea; Geisbert, Thomas; Hensley, Lisa E.; Connor, John H.

In: Antiviral Research, Vol. 87, No. 2, 08.2010, p. 187-194.

Research output: Contribution to journalArticle

Smith, DR, McCarthy, S, Chrovian, A, Olinger, G, Stossel, A, Geisbert, T, Hensley, LE & Connor, JH 2010, 'Inhibition of heat-shock protein 90 reduces Ebola virus replication', Antiviral Research, vol. 87, no. 2, pp. 187-194. https://doi.org/10.1016/j.antiviral.2010.04.015
Smith, Darci R. ; McCarthy, Sarah ; Chrovian, Andrew ; Olinger, Gene ; Stossel, Andrea ; Geisbert, Thomas ; Hensley, Lisa E. ; Connor, John H. / Inhibition of heat-shock protein 90 reduces Ebola virus replication. In: Antiviral Research. 2010 ; Vol. 87, No. 2. pp. 187-194.
@article{9bcb19e0191d4ea68173c0f863ffeb53,
title = "Inhibition of heat-shock protein 90 reduces Ebola virus replication",
abstract = "Ebola virus (EBOV), a negative-sense RNA virus in the family Filoviridae, is known to cause severe hemorrhagic fever in humans and other primates. Infection with EBOV causes a high mortality rate and currently there is no FDA-licensed vaccine or therapeutic treatment available. Recently, heat-shock protein 90 (Hsp90), a molecular chaperone, was shown to be an important host factor for the replication of several negative-strand viruses. We tested the effect of several different Hsp90 inhibitors including geldanamycin, radicicol, and 17-allylamino-17-demethoxygeldanamycin (17-AAG; a geldanamycin analog) on the replication of Zaire EBOV. Our results showed that inhibition of Hsp90 significantly reduced the replication of EBOV. Classic Hsp90 inhibitors reduced viral replication with an effective concentration at 50{\%} (EC50) in the high nanomolar to low micromolar range, while drugs from a new class of Hsp90 inhibitors showed markedly more potent inhibition. These compounds blocked EBOV replication with an EC50 in the low nanomolar range and showed significant potency in blocking replication in primary human monocytes. These results validated that Hsp90 is an important host factor for the replication of filoviruses and suggest that Hsp90 inhibitors may be therapeutically effective in treating EBOV infection.",
keywords = "Ebola virus, Hsp90, Therapeutic",
author = "Smith, {Darci R.} and Sarah McCarthy and Andrew Chrovian and Gene Olinger and Andrea Stossel and Thomas Geisbert and Hensley, {Lisa E.} and Connor, {John H.}",
year = "2010",
month = "8",
doi = "10.1016/j.antiviral.2010.04.015",
language = "English (US)",
volume = "87",
pages = "187--194",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Inhibition of heat-shock protein 90 reduces Ebola virus replication

AU - Smith, Darci R.

AU - McCarthy, Sarah

AU - Chrovian, Andrew

AU - Olinger, Gene

AU - Stossel, Andrea

AU - Geisbert, Thomas

AU - Hensley, Lisa E.

AU - Connor, John H.

PY - 2010/8

Y1 - 2010/8

N2 - Ebola virus (EBOV), a negative-sense RNA virus in the family Filoviridae, is known to cause severe hemorrhagic fever in humans and other primates. Infection with EBOV causes a high mortality rate and currently there is no FDA-licensed vaccine or therapeutic treatment available. Recently, heat-shock protein 90 (Hsp90), a molecular chaperone, was shown to be an important host factor for the replication of several negative-strand viruses. We tested the effect of several different Hsp90 inhibitors including geldanamycin, radicicol, and 17-allylamino-17-demethoxygeldanamycin (17-AAG; a geldanamycin analog) on the replication of Zaire EBOV. Our results showed that inhibition of Hsp90 significantly reduced the replication of EBOV. Classic Hsp90 inhibitors reduced viral replication with an effective concentration at 50% (EC50) in the high nanomolar to low micromolar range, while drugs from a new class of Hsp90 inhibitors showed markedly more potent inhibition. These compounds blocked EBOV replication with an EC50 in the low nanomolar range and showed significant potency in blocking replication in primary human monocytes. These results validated that Hsp90 is an important host factor for the replication of filoviruses and suggest that Hsp90 inhibitors may be therapeutically effective in treating EBOV infection.

AB - Ebola virus (EBOV), a negative-sense RNA virus in the family Filoviridae, is known to cause severe hemorrhagic fever in humans and other primates. Infection with EBOV causes a high mortality rate and currently there is no FDA-licensed vaccine or therapeutic treatment available. Recently, heat-shock protein 90 (Hsp90), a molecular chaperone, was shown to be an important host factor for the replication of several negative-strand viruses. We tested the effect of several different Hsp90 inhibitors including geldanamycin, radicicol, and 17-allylamino-17-demethoxygeldanamycin (17-AAG; a geldanamycin analog) on the replication of Zaire EBOV. Our results showed that inhibition of Hsp90 significantly reduced the replication of EBOV. Classic Hsp90 inhibitors reduced viral replication with an effective concentration at 50% (EC50) in the high nanomolar to low micromolar range, while drugs from a new class of Hsp90 inhibitors showed markedly more potent inhibition. These compounds blocked EBOV replication with an EC50 in the low nanomolar range and showed significant potency in blocking replication in primary human monocytes. These results validated that Hsp90 is an important host factor for the replication of filoviruses and suggest that Hsp90 inhibitors may be therapeutically effective in treating EBOV infection.

KW - Ebola virus

KW - Hsp90

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=77954951982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954951982&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2010.04.015

DO - 10.1016/j.antiviral.2010.04.015

M3 - Article

C2 - 20452380

AN - SCOPUS:77954951982

VL - 87

SP - 187

EP - 194

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 2

ER -